BEA-17 Granted Orphan Drug Designation By FDA For The Treatment Of Glioblastoma
Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.